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SECOND SOLID CANCER AFTER HODGKIN’S DISEASE: ANALYSIS
OF THE RISK AND REVISION OF THE LITERATURE
M. Santoro. Department of Onco-Hematology, Hospital Pugliese-
Ciaccio, Via Pio X, 88100 Catanzaro, Italy
At present time, patients with Hodgkin’s disease (HD) have a
high probability of cure. However, the late sequelae treatment-
related have a remarkable clinical importance. An increased of
second primary cancers (SPC) has been observed among long-
term survivors of HD: particularly, acute non-lymphoid leukemia
(ANLL), non-Hodgkin’ lymphoma (NHL) and secondary solid
tumours (ST).1–5 The increase of ANLL risk has been correlated
with host-related factors and the type of treatment procedures.1,5
Several authors have demonstrated that secondary ANLL was
likely with chemotherapy-treatment. NHL has been correlated
with the radiochemotherapy treatment: the risk has concentrated
in the first year following start of treatment and declined in the
subsequent 5 years.6 Recently, several studies have been focused
attention on the incidence of ST: the appearance risk increases
with the length of the follow-up (Fig. 1) and results correlated
with the kind of treatment using RT alone or in combination with
chemotherapy (CT ).1,4 The most frequent solid tumor are lung
cancer, breast cancer, melanoma skin, gastrointestinal cancer
and sarcoma of the bone.
On the occurrence of solid tumours in patients treated with CT
alone, the results of BNLI7 shows an increased risk of ST after CT
alone: further study is required for a better examination of the
increase in risk of ST after treatment with CT. Moreover, Maurizi
et al.4 show that additional therapy for relapsing patients with
CT + RT after initial therapy with RT alone does not increase the
risk of ST, while in a recent study8 the addition of combined ther-
apy for recurrent disease in patients previously treated with
radiotherapy showed a significant increase in the relative risk of
ST. In the authors’ opinion, it is possible that either the cumula-
tive dose of radiation received after secondary treatment with
CT was responsible for a high occurrence of ST or that the
increase in ST occurrence was due to initial radiation.
Age is the major risk factor of solid tumours in the HD popu-
lation, in the same way as age is a major risk factor of almost all
solid cancer in the general population. It is uncertain whether
this biological phenomenon is related to age or to the HD status
of patients or whether it is an undifferentiated effect of treatment
(RT or CT or CT + RT).
With respect to the location of ST, no definite relation could be
made between the treatment received (radiotherapy alone and
radiotherapy with chemotherapy) and the tumor tissue. For
example, lung cancer was observed more often in patients who
had received RT, but also in patients treated with CT alone. In
their detailed analysis of various solid tumours, Kaldor et al.9
have pointed out that the occurrence of lung cancer is higher in
long-term HD survivors than in the general population. They con-
clude that this higher risk is due to the cancer-inducing effects of
both CT and RT, compared with those produced by other risk fac-
tors, e.g. smoking for lung cancer. Van Leeuwen et al.10studied a
cohort of 1939 patients treated for HD who developed 30 lung can-
cers and examined the relationship between the carcinogenic
effect of smoking and radiation. They conclude that the appear-
ance of lung cancer is related both to the radiation dose received
by the lung and to smoking after radiation exposure.
Regarding the occurrence of breast cancer,Van Leeuwen
et al.11 and Yahalom et al.12 reported an increased risk of breast
cancer in women who have received radiation therapy for HD at
a younger age. Moreover, Yahalom et al.12 showed that breast can-
cer following the treatment for HD was bilateral and frequently
involved the medial half of the breast,while the prognosis of the
disease is similar to that of patients with primary cancer. In Han-
cock’s experience,13 the risk after 15 years is equivalent both in
women treated with RT alone and in women receiving RT com-
bined with MOPP. For other types of cancer such as cancer of
the gastroenteric tract, of the soft tissue and of the nervous sys-
tem, which have been observed in irradiation, there could be a
Fig. 1. Cumulative risk of solid tumour (ST).
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relation to the cancer-inducing effects of radiation after a rela-
tively short time. In conclusion, a multifactorial etiology can be
established. The appearance of ST in HD patients could be
explained by immune deficiency caused by HD itself or by the
treatment received to cure it. Genetic factors could also play a
role, leading to the appearance of a neoplasm in a small percent-
age of patients exposed to environmental factors. These is also a
higher risk, for patients who have had one tumour, of developing
another. The increased risk of ST was connected with treatment
received and with host-related and environmental factors. Since
treatment-associated cancer continues beyond 15 years, the sur-
vivors of HD should be monitored in order to establish the treat-
ment-related carcinogenic effects.
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